ArticleCancer letters2025
Preserved host immunity with intercellular adhesion molecule-1 (ICAM-1)-targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of triple-negative breast cancer and other malignancies.
Article in Cancer letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recent advances in near-infrared dye conjugates for near-infrared photoimmunotherapy (NIR-PIT): enhancing therapeutic efficacy and immune mechanisms.RSC chemical biology · 2026Review
- Igniting cold tumors: reprogramming the tumor immune microenvironment with dual-payload ADCs in combination with PD-L1&4-1BB bispecific antibodies.Journal for immunotherapy of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer treatment that combines an antibody photoabsorber-conjugate (APC) with NIR light to induce direct cytotoxicity and immunogenic cell death. Intercellular Adhesion Molecule 1 (ICAM-1), a cell surface protein overexpressed in various cancers, is a promising target for cancer therapy. We previously reported that ICAM-1-targeted NIR-PIT could be used in the treatment of ICAM-1 expressing triple-negative breast cancer (TNBC); however, ICAM-1 is also expressed on immune cells within the tumor microenvironment (TME). Therefore, the net impact of ICAM-1-targeted NIR-PIT on the tumor vs. antitumor host immunity remains unclear, posing a significant challenge to its clinical advancement. In this study, we investigated the antitumor effect of ICAM-1-targeted NIR-PIT including its influence on host immunity following NIR light irradiation, using immunocompetent mouse models. In vitro, ICAM-1-targeted NIR-PIT caused immunogenic cell death in EO771 (breast cancer) and SP2/0 (myeloma) models expressing ICAM-1. Ex vivo, ICAM-1-targeted NIR-PIT effectively eliminated ICAM-1-expressing cancer cells and immune cells within the TME. However, the net effect was to suppress tumor progression and prolong survival in EO771, MOC1 (oral carcinoma), and SP2/0 models in vivo. Enhanced antitumor host immunity was observed after ICAM-1-targeted NIR-PIT in the MOC1 model. In conclusion, ICAM-1-targeted NIR-PIT holds promise as a treatment for various cancer models expressing ICAM-1 beyond TNBC by directly killing cancer cells and enhancing host immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.